Bioventus - Class A (BVS) closed at $10.99 on November 11, 2026, down 1.7% from the previous close, on volume of 431,948 shares (30-day average 531,088).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | Calendar Call Spread | 16-Oct : 20-Nov-26 12.5 C | 300 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
3 Small-Cap Healthcare Stocks with More Than 40% Upside, According to Analysts
TipRanks (Tue, 10-Nov 6:31 AM ET)
Bioventus Reports Third Quarter Financial Results
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
Market Chameleon (Wed, 5-Aug 7:02 AM ET)
Bioventus Delivers Strong Profitability and Cash Flow Amidst Flat Sales, Reaffirms 2025 Guidance
Market Chameleon (Tue, 4-Nov 6:14 AM ET)
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Bioventus - Class A trades on the NASDAQ stock market under the symbol BVS.
As of November 12, 2026, BVS stock price declined to $10.94 with 186,262 million shares trading.
BVS has a beta of 1.05, meaning it tends to be more sensitive to market movements. BVS has a correlation of 0.06 to the broad based SPY ETF.
BVS has a market cap of $739.96 million. This is considered a Small Cap stock.
Last quarter Bioventus - Class A reported $142 million in Revenue and $.17 earnings per share. This fell short of revenue expectation by $-7 million and exceeded earnings estimates by $.01.
In the last 3 years, BVS traded as high as $15.89 and as low as $3.45.
The top ETF exchange traded funds that BVS belongs to (by Net Assets): AVUV, VTI, IWM, VXF, IWO.
BVS has outperformed the market in the last year with a return of +42.1%, while the SPY ETF gained +12.4%. However, in the most recent history, BVS shares have underperformed the stock market with its stock returning -21.0% in the last 3 month period and -25.3% for the last 2 week period, while SPY has returned -1.1% and -1.6%, respectively.
BVS support price is $10.63 and resistance is $11.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BVS shares will trade within this expected range on the day.
